Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer

Breast Cancer Research and Treatment

Volumn 49, Issue SUPPL. 1, 1998, Pages

  Lønning, Per E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aromatase; Breast cancer; Estrogens; Exemestane; Formestane; Hormones; Pharmacology; Therapy

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FORMESTANE;

AROMATIZATION; BREAST CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG PROTEIN BINDING; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

ANDROSTADIENES; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE;

EID: 0031720669     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006048722559     Document Type: Article

References (3)

1. Brodie AMH, Schwarzel WC, Shaikh AA, Brodle HJ: The effect of an aromatase inhibitor, 4-hydroxy-androstene-3.17-dione, on estrogen-dependcnt processes in reproduction and breast cancer. Endocrinology 100: 1684-1695, 1977
2. Lønning PE, Dowsett M, Powles T.J: Posfmennpansal estrogen synthesis and metabolism: Alteration caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35: 355-366, 1990
3. Volk H, Deupree RH. Goldenberg IS. Wilde RC, Carabasi RA, Escher GC: A dose response evaluation of delta-1-testololactone in advanced breast cancer. Cancer 33: 9-13, 1974